Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Future Perspectives in cSCC

November 2nd 2022

Dr Khushalani discusses challenges faced when treating patients with cSCC and shares advice for fellow colleagues who treat patients with cSCC.

An Overview of Advanced Basal Cell Carcinoma (BCC) and Currently Available Treatment Options

October 28th 2022

Dr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.

Investigational Agents for the Treatment of Advanced cSCC

October 28th 2022

Dr Hanna highlights investigational agents that are being studied for the treatment of advanced cSCC and discuss some unmet needs for cSCC.

IMC-F106C Shows Potential as T-cell Receptor–Driven Therapy in Melanoma

October 27th 2022

Omid Hamid, MD, highlights the importance of evaluating PRAME×CD3 Immune-mobilizing T cell receptor against cancer for melanoma treatment, the key benefits provided to patients through improved disease control and circulating tumor DNA reduction, and the safety profile of the therapy.

Real-World Data of Cemiplimab in Patients with Advanced cSCC

October 26th 2022

Dr Khushalani provides insights into real-world data that was recently discussed at ESMO 2022 assessing the use of cemiplimab in patients with advanced cSCC.

Role of Cemiplimab in the Neoadjuvant Setting for Patients with cSCC

October 26th 2022

Nikhil Khushalani, MD, comments on updated data evaluating the use of cemiplimab in the neoadjuvant setting for patients with cSCC.

Early Data Underscore the Potential of Neoadjuvant Immunotherapy in Advanced Resectable CSCC

October 26th 2022

Neil D. Gross, MD, FACS, discusses the current deficits in the treatment of patients with cutaneous squamous cell carcinoma in the curative setting and avenues for continued research generated by the primary analysis of the phase 2 trial examining neoadjuvant cemiplimab in this population.

Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell Carcinoma

October 21st 2022

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.

Encorafenib/Binimetinib Delivers Prolonged Survival in BRAF V600–Mutant Melanoma

October 21st 2022

The combination of encorafenib and binimetinib led to sustained improvements in progression-free survival and overall survival, without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the phase 3 COLUMBUS trial.

Immunotherapy and BRAF-Targeted Therapy Fill Expanded Roles Across Melanoma

October 21st 2022

Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing.

Review of Updated Efficacy and Safety Data from the EMPOWER-CSCC-1 Trial

October 21st 2022

Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual ESMO and ASCO 2022 meetings.

Current Treatment Options for Patients with Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

October 21st 2022

Glenn J Hanna, MD, provides a brief overview of cutaneous squamous cell carcinoma (cSCC), and discusses the currently available treatment options for patients with advanced cSCC.

Dr. Gross on the Investigation of Cemiplimab in Cutaneous Squamous Cell Carcinoma

October 20th 2022

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.

Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma

October 20th 2022

Adjuvant treatment with nivolumab resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival over placebo in patients with completely resected stage IIB or IIC melanoma.

Treatment Options for Patients with cSCC in the Neoadjuvant Setting

October 19th 2022

An overview of treatment options for patients for with cSCC, focusing on the neoadjuvant setting.

Overview of Cutaneous Squamous Cell Carcinoma (cSCC)

October 19th 2022

Dr Khushalani defines cutaneous squamous cell carcinoma (cSCC), reviews the risk factors associated, and explains the staging system for patients diagnosed with cSCC.

Dr. Yorio on Treatment Combinations in BRAF-Mutated Melanoma

October 13th 2022

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.

Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma

October 12th 2022

Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.

Checkpoint Inhibition Prevails as Frontline Standard in BRAF-Mutant Melanoma

October 11th 2022

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

FDA Approval Sought for Denileukin Diftitox for Persistent or Recurrent Cutaneous T-cell Lymphoma

October 4th 2022

A biologics license application seeking the approval of a reformulation of denileukin diftitox for use as a potential therapeutic option in patients with persistent or recurrent cutaneous T-cell lymphoma has been submitted to the FDA.